Prednisolone 1 mg and 5 mg Tablets and Oral Liquid: Prescription Active-Form Corticosteroid for Inflammatory, Autoimmune, and Respiratory Conditions — Preferred in Hepatic Insufficiency

Information last reviewed: May 2026 — for educational purposes only.

Prednisolone is the biologically active metabolite of prednisone — the form of the drug that actually binds glucocorticoid receptors and exerts anti-inflammatory and immunosuppressive effects. When prednisone is taken orally, it is rapidly converted to prednisolone by the enzyme 11-beta-hydroxysteroid dehydrogenase (11-beta-HSD) in the liver. Because this conversion requires a functioning liver, patients with significant hepatic insufficiency (hepatic cirrhosis, severe liver disease) may not reliably convert prednisone to prednisolone — potentially receiving less than the intended therapeutic effect. For such patients, prescribing prednisolone directly bypasses the hepatic conversion step and ensures reliably predictable pharmacological activity.

In most patients with normal hepatic function, prednisone and prednisolone are clinically interchangeable at equivalent doses (1 mg prednisone ≈ 1 mg prednisolone in anti-inflammatory effect). The choice between them is largely a matter of clinical context: prednisone is more widely available in more strength options and is typically the default drug; prednisolone is specified when liver disease is present, when rapid onset is critical, or when the liquid formulation is needed (prednisolone oral liquid is more widely available than prednisone liquid in many markets, making it preferable for children and patients who cannot swallow tablets).

What Is Prednisolone?

Prednisolone is an intermediate-acting synthetic glucocorticoid with a plasma half-life of approximately 2–4 hours but a biological (receptor-level) half-life of 12–36 hours — allowing once or twice daily dosing for most indications. It has moderate mineralocorticoid activity (sodium and water retention potential), less than hydrocortisone but more than methylprednisolone or dexamethasone. Anti-inflammatory potency: 4–5× cortisol, approximately equivalent to prednisone. Prednisolone is the active form of both prednisone (prodrug) and itself (direct-acting). As with all systemic corticosteroids, courses longer than 1–2 weeks require tapering and courses longer than 1 month significantly suppress the HPA axis.

Prescription Status

Prednisolone is prescription-only in the United States in all oral forms. It is not available OTC. Indication-appropriate prescribing and monitoring by a healthcare provider is required.

Strengths and Available Forms

• Prednisolone 1 mg tablets — for low-dose chronic inflammatory conditions (e.g. rheumatoid arthritis maintenance, polymyalgia rheumatica tapering); allows fine dose titration in mg increments
• Prednisolone 5 mg tablets — standard dose unit; equivalent to prednisone 5 mg; for moderate-dose inflammatory, allergic, and autoimmune conditions; also used for asthma exacerbation short courses
• Prednisolone oral solution 5 mg/5 mL (1 mg/mL) — liquid for children, patients with dysphagia, and those requiring precise dose adjustment; can be mixed with juice or food
• Prednisolone oral solution 15 mg/5 mL (3 mg/mL) — higher-concentration liquid for larger doses without large volumes
• Prednisolone ODT (orally disintegrating tablet) 10/15/30 mg — dissolves on tongue without water; for paediatric asthma and patients unable to swallow tablets

Common dosing regimens: Asthma exacerbation in adults: 40–60 mg/day prednisolone for 5–7 days, then stop (no taper needed for short courses ≤2 weeks in non-HPA-suppressed patients). Inflammatory conditions: doses vary widely by condition, severity, and patient size — individualised by physician.

Price of Prednisolone Tablets and Oral Solution

Generic prednisolone tablets (1 mg, 5 mg) are inexpensive. The oral solution costs more per mg than tablets. Most insurance plans cover prednisolone; paediatric liquid formulations may have higher cost shares. For the short-course asthma or allergy indications, prednisolone remains one of the most cost-effective treatment options available.

Frequently Asked Questions

Why is prednisolone preferred over prednisone in liver disease?

Prednisone is a prodrug that requires hepatic 11-beta-HSD conversion to the active prednisolone before it can bind glucocorticoid receptors. In patients with cirrhosis, alcoholic hepatitis, or severe hepatic insufficiency, this conversion is impaired — studies have shown significantly lower prednisolone plasma levels after equivalent prednisone doses in cirrhotic patients compared to those with normal livers, meaning cirrhotic patients may experience substantially less anti-inflammatory effect from prednisone. By prescribing prednisolone directly, the hepatic activation step is bypassed — drug plasma levels and efficacy are predictable regardless of liver function. This is clinically important because autoimmune hepatitis (treated with prednisolone/prednisone) and inflammatory conditions in chronic liver disease patients are scenarios where choosing prednisolone over prednisone is appropriate.

How does prednisolone dosing differ in children (paediatric asthma)?

Prednisolone is the preferred oral corticosteroid for treating acute asthma exacerbations in children. The standard paediatric dose is 1 mg/kg/day (maximum 40 mg/day) for 3–5 days — given as a single daily morning dose. Studies comparing 3-day and 5-day courses have shown equivalent outcomes for mild-to-moderate paediatric asthma exacerbations, with the 3-day course improving adherence. The oral liquid formulation makes it practical for young children who cannot swallow tablets. No taper is required for courses of 5 days or less.

What are the long-term effects of prednisolone when used chronically?

Long-term oral prednisolone (months to years) for conditions such as rheumatoid arthritis, polymyalgia rheumatica, or chronic autoimmune disease causes a predictable cluster of side effects: osteoporosis (calcium and bisphosphonate supplementation recommended for courses >3 months at ≥7.5 mg/day); weight gain and cushingoid features (moon face, central obesity, buffalo hump); glucose intolerance and steroid-induced diabetes; hypertension; increased infection susceptibility; cataracts and glaucoma; skin thinning; muscle weakness (proximal myopathy); and HPA axis suppression requiring tapering. These considerations mean that long-term steroid prescribing requires regular clinical review, bone density monitoring, and active steroid-sparing strategy planning to minimise cumulative dose.

← Back to Corticosteroids